Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients. by Moroni, M. et al.
Britsh Journal of Cancer (1996) 74, 309-311
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 Wt
SHORT COMMUNICATION
Inhaled sodium cromoglycate to treat cough in advanced lung cancer
patients
M Moroni', C Portal, G Gualtieri2, G Nastasil and C Tinelli3
'Istituto di Terapia Medica, 2Divisione di Tisiologia and 3Servizio di Biometria e Statistica Medica, IRCCS Policlinico San Matteo,
Universita di Pavia, Piazzale Camillo Golgi, 1-27100 Pavia, Italy.
Summary C-fibres probably represent the common final pathway in both ACE inhibitors and neoplastic
cough. A recent report demonstrated that inhaled sodium cromoglycate is an effective treatment for ACE
inhibitors' cough; this effect might be due to the suppression of afferent unmyelinated C-fibres. We tested the
hypothesis that inhaled sodium cromoglycate might also be effective in lung cancer patients who presented with
irritative neoplastic cough. Twenty non-small-cell lung cancer (NSCLC) patients complaining ofcough resistant
to conventional treatment were randomised to receive, in a double-blind trial, either inhaled sodium
cromoglycate or placebo. Patients recorded cough severity daily, before and during treatment, on a 0 to 4 scale.
The efficacy of treatment was tested with the Mann-Whitney U-test for non-parametric measures, comparing
the intergroup differences in the measures of summary of symptom scores calculated in each patient before and
after treatment. We report that inhaled sodium cromoglycate can reduce cough, also in NSCLC patients and
that such reduction, observed in all patients treated, is statistically significant (P<0.001). Inhaled sodium
cromoglycate appears to be a cost-effective and safe treatment for lung cancer-related cough.
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Cough is a common and distressing symptom in non-small-
cell lung cancer (NSCLC) patients, which is observed in
about 71% of the patients presenting with unresectable
disease (Hollen et al., 1993).
Opioids remain among the most effective agents for
suppressing cough, but unfortunately they exhibit a wide
spectrum of unwanted effects; indeed, the protracted use of
opioids needs great caution in any case of decreased
respiratory reserve (Jaffe and Martin, 1990). Furthermore,
some patients fail to respond to opioid-based antitussive
therapy or develop resistance to these compounds.
A recent report (Hargreaves and Benson, 1995) demon-
strated that inhaled sodium cromoglycate is an effective
treatment for angiotensin-converting enzyme (ACE) inhibi-
tors' cough; this effect might be due to the suppression of
afferent vagal activity and of unmyelinated C-fibres in
particular.
Since a role of C-fibres can be postulated also in cancer-
related cough, we tested the hypothesis that inhaled sodium
cromoglycate, as an inhibitor of these fibres, might be
effective also in lung cancer patients who presented with
irritative and resistant neoplastic cough.
Materials and methods
After obtaining informed consent, and according to
institutional requirements for clinical trials, we randomised
20 patients with locally advanced or unresectable metastatic
NSCLC and irritative neoplastic cough resistant to conven-
tional treatment, to receive, in a double-blind trial, either
inhaled sodium cromoglycate or placebo (inhaled physiolo-
gical solution). Patients' characteristics are summarised in
Table I. Non-neoplastic causes for cough i.e. bronchial
asthma, acute respiratory airways' infections, heart failure,
tuberculosis, bronchiectasias, ACE inhibitors' therapy, were
ruled out before enrolling the patients in this study. To rule
out the presence of associated bronchial asthma, clinical
findings, including IgE and eosinophils titration, and case
histories were studied.
In the patients already affected with chronic bronchitis, in
the absence of the above causes for cough, we considered the
recent onset of dry and irritative cough to suffice to diagnose
neoplastic cough.
Moreover, all specific anti-cancer treatments had been
discontinued in all patients at least 3 weeks earlier, because of
tumour progression, while previous antitussive agents had
been suspended for at least 1 week.
The patients were instructed to inhale two puffs four
scheduled times a day (the total dose of the drug was 40 mg
per day) for 2 weeks and to report every morning, on a 0 to 4
scale, the severity of their cough the day before, for three
consecutive days before treatment and thereafter every day
during treatment. Cough was graded as 0, no cough; 1, mild
cough; 2, moderate cough; 3, fairly severe cough; 4, very
severe cough (Hargreaves and Benson, 1995), according to
both intensity and frequency.
In agreement with Matthews' guidelines for the analysis of
serial measurements in medical research (Matthews et al.,
1990), treatment efficacy was tested with the Mann-Whitney
U-test for non-parametric measures. Thus, we compared the
intergroup differences in the measures of summary of
symptom scores, before and after treatment, in each
patient; as a pretreatment measure of summary, we
considered in each patient, the average score of the 3 days
immediately before sodium cromoglycate or placebo admin-
istration, while the post-treatment measure of summary was,
once again in each patient, the average ofthe 14 on-treatment
scores. Then, the individual behaviour of cough intensity was
illustrated graphically (Matthews et al., 1990).
Data were elaborated using the Statistica/W package for
Windows (Statsoft Inc., Tulsa, OK, USA).
Results
Mean daily cough score during the 3 days' run-in period was
3.1 in the sodium cromoglycate group (median: 3.2, 25°-75°
percentile: 2.3-3.7) and 3.03 in the placebo group (median:
3.2, 25°-75° percentile: 2.3-3.7). After treatment, mean daily
cough score was 1.6 (median: 1.4, 25°-750 percentile: 1.4-1.8)
in sodium cromoglycate-treated subjects and 2.9 (median: 2.9,
250-750 percentile: 2.1-3.6) in controls.
Cough intensity scores were compared in the two groups:
the reduction in cough intensity in the sodium cromoglycate
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Table I Patients' characteristics
Patients treated
with sodium Patients treated
cromoglycate with placebo
Number
Males-females
Age (years)
Average
Range
Histology
Non-small-cell
adenocarcinoma
Squamous cell
TNM stage at study start
IIIb
IV
Previous chemotherapy
Vinorelbine+cisplatin
Fluorofolates +
vinorelbine and cisplatin
Previous radiation therapy
Previous antitussive treatment
Clobutinol
Codeine
Dextrometorphane
Ambroxol
10
8:2
65.6
55-74
10
6
4
4
6
5
5
2
4
4
10
0
10
7:3
62.7
52-71
10
5
5
3
7
3
7
2
2
6
8
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group was statistically significant (P<0.001) relative to
placebo controls. Pre- vs post-treatment cough intensity
changes, as reported by each patient, and the average in
each group, are reported in Figure 1. As the graph shows
clearly, cough neither worsened nor remained stable in any
sodium cromoglycate patient, different from placebo controls.
The above data strongly confirm that there is an overall
effect of treatment; even though there are too few patients to
make a strong statement concerning the time course of the
treatment effect, we observed that typically there was a delay
of 36-48 h before a cromoglycate effect became apparent.
Sodium cromoglycate treatment caused no acute side-
effects or allergic reactions and was well accepted by the
patients. Soon after sodium cromoglycate withdrawal, cough
rapidly reappeared in all patients; after we had analysed the
results of our study, the patients in both the treated and
placebo groups were successfully retreated with sodium
cromoglycate.
Discussion
ACE inhibition and lung cancer probably share a common
final pathway in evoking cough, the afferent stimulus
conducted by C-fibres. As a matter of fact, after ACE
inhibition, bradykinin accumulates in the lung because of the
inhibition of kininase II, which is responsible for its
breakdown (Ryan, 1982); bradykinin stimulates unmyeli-
nated C-fibres within the bronchial wall (Kaufman et al.,
1980; Fuller et al., 1987), thus starting the tussive reflex
(Coleridge and Coleridge, 1994).
In lung cancer, bradykinin is one of the many
neuropeptides produced by neoplastic cells, which act as
paracrine or autocrine growth factors (Bunn et al., 1990,
1992). Moreover, mechanical stimuli due to the tumour itself
contribute to evoke cough; since C-fibre endings' sensitivity
to distortion allows them to function as interstitial stretch
receptors (Coleridge and Coleridge, 1994; Paintal, 1969) their
involvement in the tussive reflex can be postulated.
Hargreaves and Benson (1995) recently demonstrated that
inhaled sodium cromoglycate is able to suppress ACE
inhibitor cough, probably via an inhibition of C-fibres.
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Figure 1 Symptom intensity changes reported by each patient
before and after treatment. The pretreatment score is the average
of the three run-in scores (measure of summary pretreatment)
while the post-treatment score is the average score of the 14 days
of sodium cromoglycate vs placebo administration (measure of
summary post-treatment). The thicker line represents the average
trend in each group.
We report that this safe and cost-effective drug can also
reduce cough in NSCLC patients; such reduction, observed in
all treated patients, was statistically significant. Further
studies on larger series are nevertheless needed to confirm
these encouraging preliminary results.
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